Publications by authors named "Zenta Seto"

Claim this Profile
T
TTF-1 expression is associated with survival in patients with non-squamous non-small cell lung cancer treated with immune checkpoint inhibitor therapy.
Nozomu Murayama, Minehiko Inomata, Daisuke Furukawa, Moe Hashizume, Naoki Takata, Zenta Seto

Mol Clin Oncol· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer.
Zenta Seto, Minehiko Inomata, Akira Noguchi, Tomonobu Kado, Nozomu Murayama

Cancer Rep (Hoboken)· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter Retrospective Analysis of Pulmonary Sarcomatoid Carcinoma Clinically Diagnosed Using Small Biopsy Specimens.
Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Zenta Seto

Cancer Diagn Progn· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Chemoimmunotherapy in Small-cell Lung Cancer Patients With a Poor Performance Status or Higher Neutrophil/Lymphocyte Ratio.
Minehiko Inomata, Naoki Takata, Zenta Seto, Nozomu Murayama, Kotaro Tokui

In Vivo· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma.
Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizusihima, Kenji Azechi, Zenta Seto

Discov Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.
Minehiko Inomata, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Zenta Seto

Mol Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
Takahiro Hirai, Minehiko Inomata, Shuhei Minatoyama, Moe Hashizume, Naoki Takata, Zenta Seto

In Vivo· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy.
Minehiko Inomata, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Zenta Seto

Anticancer Res· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors.
Minehiko Inomata, Masahiro Matsumoto, Kana Hayashi, Zenta Seto, Takahiro Hirai

Anticancer Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto

Sci Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice.
Minehiko Inomata, Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizushima, Zenta Seto

Thorac Cancer· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer.
Minehiko Inomata, Masahiro Matsumoto, Isami Mizushima, Zenta Seto, Kana Hayashi

Cancer Diagn Progn· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
Zenta Seto, Naoki Takata, Nozomu Murayama, Kotaro Tokui, Seisuke Okazawa

Tumori· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between Patient Characteristics and the Timing of Provision of Explanation about DNAR to Patients with Advanced Lung Cancer.
Minehiko Inomata, Takahiro Hirai, Naoki Takata, Nozomu Murayama, Kana Hayashi, Zenta Seto

Intern Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy.
Minehiko Inomata, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka

Pathol Oncol Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis